Dengue vaccine, pharmaceutical composition comprising the same, nucleotide sequence and antibody composition
AssigneeNational Cheng Kung University
InventorYee-Shin Lin
Life of this patent
Estimating the term…
Abstract
The present invention relates to a dengue vaccine, a pharmaceutical composition comprising the same, a nucleotide sequence, and an antibody composition. The dengue vaccine of the present invention includes chimeric nonstructural protein 1, which comprises N-terminus of DV NS1 from amino-acid residues 1 to 270 and C-terminus of JEV NS1 from amino-acid residues 271 to 352 (designated DJ NS1). Therefore, the dengue vaccine without autoimmunity according to the present invention is able to avoid cross-reactions with endothelial cells and platelets, and is able to shorten the bleeding time.
Claims5
A composition comprising a chimeric nonstructural protein DJ NS1, wherein the chimeric nonstructural protein DJ NS1 comprises:
- a sequence having at least 95% sequence identity with the N-terminus of the dengue virus nonstructural protein 1 (DV NS1) from amino acids 1 to 270 of SEQ ID NO:
- 1;
- and
- a sequence having at least 95% sequence identity with the C-terminus of Japanese encephalitis virus nonstructural protein 1 (JEV NS1) from amino acids 271 to 352 of SEQ ID NO:
- 1.
A composition comprising a chimeric nonstructural protein DJ NS1, wherein the chimeric nonstructural protein DJ NS1 comprises an amino acid sequence having at least 95% sequence identity with SEQ ID NO:
- 1.
Dependencies are inferred from the claim text.